In a recent announcement, President Trump introduced a plan aimed at making in vitro fertilization (IVF) more affordable for families across the nation. This initiative includes collaboration with pharmaceutical companies to reduce drug prices and expand employer-sponsored fertility benefits. Despite some positive receptions from industry advocates, the announcement has drawn criticism from various quarters, including US bishops and some conservative factions. Key stakeholders worry that while the plan may lower costs for some, it may not fulfill all promised benefits. Discussions continue regarding the potential impact of these changes on access to fertility treatments and the ethical implications associated with new policies.